Relmada Therapeutics (RLMD) Other Non Operating Income (2014 - 2020)
Relmada Therapeutics (RLMD) posted quarterly Other Non Operating Income of -$934919.0 for Q1 2020, down 46746050.0% year-over-year from N/an in Q2 2019, and down 46746050.0% quarter-over-quarter from $2.0 in Q1 2019.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Other Non Operating Income (2014 - 2020) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Other Non Operating Income for 7 consecutive years, with -$934919.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Other Non Operating Income fell 46746050.0% year-over-year to -$934919.0; the TTM figure through Mar 2020 stood at -$671010.0 (up 20.5% YoY), while the FY2019 annual figure was -$54634.0, up 92.29% from the prior year.
- Other Non Operating Income retreated to -$934919.0 in Q1 2020 per RLMD's latest filing, from $2.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $13.0 million in Q2 2016 and bottomed at -$934919.0 in Q1 2020.
- Historically, Other Non Operating Income has averaged $883366.9 across 5 years, with a median of $28455.5 in 2016.
- Annual changes were most pronounced in 2016 — Other Non Operating Income soared 7840.17% — and 2020, when it plunged 46746050.0%.
- Relmada Therapeutics' Other Non Operating Income stood at $56909.0 in 2016, then surged by 499.39% to $341106.0 in 2017, then dropped by 22.63% to $263907.0 in 2018, then sank by 100.0% to $2.0 in 2019, then slumped by 46746050.0% to -$934919.0 in 2020.
- Business Quant data shows RLMD's Other Non Operating Income at -$934919.0 in Q1 2020, $2.0 in Q1 2019, and $263907.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -934,919.00 |
| Dec 31, 2018 | -3.77 Mn |
| Sep 30, 2018 | -318,541.00 |
| Jun 30, 2018 | -789,443.00 |
| Mar 31, 2018 | -254,862.00 |
| Dec 31, 2017 | 341,106.00 |
| Sep 30, 2017 | -5,702.00 |
| Jun 30, 2017 | -66,395.00 |
| Mar 31, 2017 | 301,458.00 |
| Dec 31, 2016 | 505,572.00 |
| Sep 30, 2016 | -80,043.00 |
| Jun 30, 2016 | -214,918.00 |
| Mar 31, 2016 | 887,308.00 |
| Dec 31, 2015 | 3.26 Mn |
| Sep 30, 2015 | 9.29 Mn |
| Jun 30, 2015 | 10.47 Mn |
| Mar 31, 2015 | 2.12 Mn |
| Dec 31, 2014 | 9.84 Mn |
| Sep 30, 2014 | -26.12 Mn |
| Jun 30, 2014 | -8.39 Mn |